VitaSpring Biomedical Past Earnings Performance
Past criteria checks 3/6
There is insufficient data on VitaSpring Biomedical's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 109.9% |
| Return on equity | 55.6% |
| Net Margin | 18.8% |
| Last Earnings Update | 31 Oct 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How VitaSpring Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Oct 22 | 5 | 1 | 1 | 0 |
| 31 Jul 22 | 5 | 1 | 1 | 0 |
| 30 Apr 22 | 7 | 1 | 1 | 0 |
| 31 Jan 22 | 6 | 1 | 1 | 0 |
| 31 Oct 21 | 2 | 0 | 1 | 0 |
| 31 Jul 21 | 2 | 0 | 1 | 0 |
| 30 Apr 21 | 1 | 0 | 1 | 0 |
| 31 Jan 21 | 0 | 0 | 1 | 0 |
| 31 Jul 20 | 0 | 0 | 0 | 0 |
| 30 Apr 20 | 0 | 0 | 0 | 0 |
| 31 Jan 20 | 0 | 0 | 0 | 0 |
| 31 Oct 19 | 0 | 0 | 0 | 0 |
| 31 Jul 19 | 0 | 0 | 0 | 0 |
| 30 Apr 19 | 0 | 0 | 0 | 0 |
| 31 Jan 19 | 0 | 0 | 0 | 0 |
| 31 Oct 18 | 0 | 0 | 0 | 0 |
| 31 Jul 18 | 0 | 0 | 0 | 0 |
| 30 Apr 18 | 0 | 0 | 0 | 0 |
| 31 Jan 18 | 0 | 0 | 0 | 0 |
Quality Earnings: VSBC has a high level of non-cash earnings.
Growing Profit Margin: VSBC became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VSBC has become profitable over the past 5 years.
Accelerating Growth: VSBC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: VSBC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: VSBC's Return on Equity (55.6%) is considered outstanding.